The TROP-2 targeted therapy market presents key opportunities driven by rising cancer prevalence, particularly in challenging tumor types. Growth is supported by advancements in precision medicine, ...
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 ...
First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC). This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results